Application of human bone mesenchymal stem cells to preparation of medicament for treating ankylosing spondylitis

Abstract

The invention discloses application of human bone mesenchymal stem cells (BMSC) to preparation of a medicament for treating ankylosing spondylitis (AS). Aiming at the condition that the MSC immunoregulation ability of an AS patient is reduced, Th17 cannot be inhibited and Treg cannot be up-regulated, the imbalanced ratio of Th17 to Treg causes that the whole body of the AS patient is in an inflammatory state, meanwhile the MSC bone formation ability of the AS patient is increased to cause the pathological bone formation of the AS patient, the factors result in potential etiological factors of the ankylosing spondylitis. Healthy BMSCs are intravenously infused to the AS patient to regulate disorder immunologic functions, and the pathological bone formation of the MSCs is inhibited to alleviate or change the disease progression. The effect on the patient is very obvious, the disease improvement condition of the patient is satisfactory, the BMSCs can be used for assisting the patient to reduce or even stop taking medicaments, such as NSAID (Non Steroidal Anti Inflammatory Drugs) and the like, and are safe and effective without any adverse side effect. The BMSCs are wide in source, and the treatment cost is reasonable, so that the BMSCs has tremendous social and economic benefits when being applied to preparation of the medicament for treating ankylosing spondylitis.

Description

Technical field: [0001] The invention belongs to the field of medicine, and in particular relates to the application of human bone marrow mesenchymal stem cells in the preparation of medicines for treating ankylosing spondylitis. Background technique: [0002] Ankylosing spondylitis (AS) is a common autoimmune disease, mainly involving axial joints and tendon attachment points, with inflammatory back pain and asymmetric peripheral arthritis as the main symptoms, and it is more common in young people. Most of the onset is between 23 and 30 years old, and the male to female ratio is about 2:1. According to reports from Europe, the prevalence of AS is 0.15%-1.8%, and the epidemiological survey data of 120,451 Han people in 12 provinces and cities in my country shows that the prevalence of AS is 0.2%-0.54%. The main pathological features of AS are autoimmune inflammation and pathological osteogenesis, which is a highly disabling disease. With the development of the disease, it ...

AI Technical Summary

Problems solved by technology

[0017] At present, the specific marker molecules of MSC have not been screened, but the consensus view is that SH2, SH3, CD29, CD44, CD71, CD90, CD102, etc. are positive, while CD14, CD34, CD45 and other hematopoietic lineage molecules are negative